NAB1

NAB1 is a nuclear transcriptional corepressor that physically interacts with the inhibitory domain of Egr-family transcription factors (specifically NGFI-A/Egr-1 and Krox20, but not Egr3) to repress their transcriptional activity (PMID:7624335). Repression is mediated by an active mechanism localized to the conserved NCD2 domain in the C-terminus and does not operate by blocking DNA binding or nuclear localization; NAB1 possesses intrinsic, position-independent repressor activity when tethered to a promoter (PMID:9418898, PMID:11018254). NAB1 expression is induced by lipid mediators such as aspirin-triggered lipoxin A4 via G protein-coupled receptor signaling and by histone deacetylase inhibitors such as valproic acid, and NAB1 is recruited to specific target promoters (e.g., mPGES-1) to suppress Egr-1-dependent inflammatory gene expression (PMID:11687510, PMID:21239760).

1. 1995 High

   Identification of NAB1 as an Egr-family corepressor resolved how NGFI-A and Krox20 transcriptional activity is negatively modulated through their inhibitory domains, while establishing selectivity within the Egr family (no interaction with Egr3).

   Evidence Yeast two-hybrid screen and transcriptional repression assays

   PMID:7624335

   Open questions at the time

   • Mechanism of repression (passive vs. active) was not determined
   • No mapping of the repression domain within NAB1
   • In vivo relevance not tested
2. 1998 High

   Dissection of NAB1 domain architecture established that repression is an active, NCD2-dependent mechanism independent of blocking DNA binding or nuclear entry, resolving the question of how NAB1 silences transcription after being recruited to Egr targets.

   Evidence Systematic deletion and replacement mutagenesis with tethered repression assays and nuclear localization analysis

   PMID:9418898

   Open questions at the time

   • Identity of downstream effectors recruited by NCD2 (e.g., histone deacetylases, chromatin remodelers) was not determined
   • Structural basis of NCD2-mediated repression unknown
3. 2000 High

   Demonstration that GAL4-NAB1 represses transcription from both proximal and distal promoter positions confirmed that NAB1 harbors intrinsic repressor activity independent of its Egr-docking mechanism, strengthening the model that Egr-1's inhibitory domain serves solely as a recruitment platform.

   Evidence GAL4-tethered repression and co-expression assays in human cell lines

   PMID:11018254

   Open questions at the time

   • Native chromatin context not examined
   • Genome-wide target repertoire unknown
4. 2001 Medium

   Discovery that aspirin-triggered lipoxin A4 rapidly induces NAB1 expression through a pertussis toxin-sensitive GPCR pathway placed NAB1 within anti-inflammatory lipid mediator signaling, revealing an upstream regulatory input.

   Evidence Differential display RT-PCR with pertussis toxin blockade in human neutrophils and in vivo murine lung model

   PMID:11687510

   Open questions at the time

   • Specific GPCR identity not established
   • Downstream Egr-dependent gene targets in neutrophils not characterized
   • Single-lab finding without independent replication
5. 2011 Medium

   Showing that valproic acid induces NAB1 recruitment to the mPGES-1 promoter and that siRNA knockdown of NAB1 abolishes suppression of mPGES-1 provided the first direct chromatin-level evidence of NAB1 functioning at a specific endogenous inflammatory gene locus.

   Evidence Chromatin immunoprecipitation, siRNA knockdown, and promoter-reporter assays in IL-1β-stimulated chondrocytes

   PMID:21239760

   Open questions at the time

   • Whether NAB1 directly or indirectly modulates histone modifications at the mPGES-1 locus was not tested
   • Generalizability to other Egr-1 target promoters not demonstrated
   • Single-lab finding
6. 2025 Medium

   Identification of a circNAB1-encoded protein (NAB1-356) that interacts with EGR1 and regulates Runx1/Gadd45b transcription to reduce atrial fibrosis extended the NAB1 functional paradigm to circular RNA-derived products with in vivo cardioprotective roles.

   Evidence CircRNA sequencing, transgenic mouse overexpression model, protein-protein interaction and functional assays

   PMID:40145839

   Open questions at the time

   • Relationship between NAB1-356 and full-length NAB1 repressor activity is unclear
   • Whether NAB1-356 uses the NCD2 mechanism is not established
   • Single-lab finding with a novel protein requiring independent confirmation

• The cofactors and chromatin-modifying complexes recruited by the NCD2 repression domain remain unidentified, and no genome-wide map of NAB1 occupancy at endogenous loci exists.
• No proteomic identification of NCD2-interacting effectors
• No ChIP-seq or CUT&RUN genome-wide occupancy data
• No structural model of NAB1 or NAB1-Egr complex